FibroBiologics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
FBLG$0.92-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
Balance Sheets
(in thousands, except shares and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $9,163 | $2,266 |
| Prepaid expenses | 36 | 29 |
| Parent company receivable | — | 300 |
| Other current assets | 16 | 30 |
| Total current assets | 9,215 | 2,625 |
| Property and equipment, net | 797 | — |
| Operating lease right-of-use asset, net | 1,809 | 2,199 |
| Total assets | $11,821 | $4,824 |
| Liabilities and stockholders’ equity/(deficit) | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $1,444 | $758 |
| Parent company payable | 141 | — |
| Operating lease liability, short-term | 362 | 326 |
| Liability instrument | 7,236 | — |
| Derivative liability | — | 538 |
| Convertible notes payable, net of debt discount | — | 5,451 |
| Total current liabilities | 9,183 | 7,073 |
| Operating lease liability, long-term | 1,385 | 1,747 |
| Total liabilities | 10,568 | 8,820 |
| Stockholders’ equity/(deficit) | ||
| Net Parent investment | — | 1,461 |
| Preferred Stock, $0.00001 par value; 8,750,000 Series A Preferred shares authorized, issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Preferred Stock, $0.00001 par value; 5,000,000 Series B Preferred shares authorized; 4,171,445 shares issued and outstanding as of December 31, 2023; 381,658 shares issued and outstanding as of December 31, 2022 | — | — |
| Preferred Stock, $0.00001 par value; 5,000,000 Series B-1 Preferred shares authorized; 89,781 shares issued and outstanding as of December 31, 2023; no shares issued and outstanding as of December 31, 2022 | — | — |
| Preferred Stock, $0.00001 par value; 2,500 Series C Preferred shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Non-voting Common Stock, $0.00001 par value; 30,000,000 shares authorized; 28,230,842 shares issued and outstanding as of December 31, 2023, and 2022 | 1 | 1 |
| Voting Common Stock, $0.00001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Additional paid-in capital | 25,609 | 2,414 |
| Accumulated deficit | (24,357) | (7,872) |
| Total stockholders’ equity/(deficit) | 1,253 | (3,996) |
| Total liabilities and stockholders’ equity/(deficit) | $11,821 | $4,824 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.